Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.

Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, Portell A, Lizotte PH, Aref AR, Eliane JP, Hammond MR, Vitzthum H, Blackmon SM, Li B, Gopalakrishnan V, Reddy SM, Cooper ZA, Paweletz CP, Barbie DA, Stemmer-Rachamimov A, Flaherty KT, Wargo JA, Boland GM, Sullivan RJ, Getz G, Hacohen N.

Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.

PMID:
30388456
2.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Oct 25. doi: 10.1038/s41591-018-0252-y. [Epub ahead of print]

PMID:
30361511
3.

Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Oct 25. doi: 10.1038/s41591-018-0251-z. [Epub ahead of print]

PMID:
30361510
4.

Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA.

Nat Med. 2018 Nov;24(11):1649-1654. doi: 10.1038/s41591-018-0197-1. Epub 2018 Oct 8. Erratum in: Nat Med. 2018 Oct 25;:. Nat Med. 2018 Oct 25;:.

PMID:
30297909
5.

Randomised controlled trial of the Limit of Detection of Troponin and ECG Discharge (LoDED) strategy versus usual care in adult patients with chest pain attending the emergency department: study protocol.

Carlton E, Campbell S, Ingram J, Kandiyali R, Taylor H, Aziz S, Beresford P, Kendall J, Reuben A, Smith J, Vickery PJ, Benger JR.

BMJ Open. 2018 Oct 2;8(10):e025339. doi: 10.1136/bmjopen-2018-025339.

6.

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y.

Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12.

PMID:
30209080
7.

Acute Liver Failure of Indeterminate Etiology: A Comprehensive Systematic Approach by An Expert Committee to Establish Causality.

Ganger DR, Rule J, Rakela J, Bass N, Reuben A, Stravitz RT, Sussman N, Larson AM, James L, Chiu C, Lee WM; Acute Liver Failure Study Group.

Am J Gastroenterol. 2018 Sep;113(9):1319-1328. doi: 10.1038/s41395-018-0160-2. Epub 2018 Jun 27.

PMID:
29946176
8.

Childhood Lead Exposure and Adult Neurodegenerative Disease.

Reuben A.

J Alzheimers Dis. 2018;64(1):17-42. doi: 10.3233/JAD-180267.

PMID:
29865081
9.

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.

Andrews MC, Reuben A, Gopalakrishnan V, Wargo JA.

Front Immunol. 2018 May 4;9:946. doi: 10.3389/fimmu.2018.00946. eCollection 2018. Review.

10.

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma.

Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ.

Oncoimmunology. 2018 Feb 1;7(5):e1423172. doi: 10.1080/2162402X.2017.1423172. eCollection 2018.

PMID:
29721378
11.

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.

Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA.

Cancer Cell. 2018 Apr 9;33(4):570-580. doi: 10.1016/j.ccell.2018.03.015. Review.

PMID:
29634945
12.

Reply: Carbohydrate Deficient Transferrin in Patients with Cirrhosis: A Tale of Bridges.

Stewart SH, Reuben A, Anton RF.

Alcohol Alcohol. 2018 May 1;53(3):351-352. doi: 10.1093/alcalc/agy009. No abstract available.

PMID:
29462240
13.

An Analysis of the Clinical, Laboratory, and Histological Features of Striped, Punctate, and Nodular Gastric Antral Vascular Ectasia.

Thomas A, Koch D, Marsteller W, Lewin D, Reuben A.

Dig Dis Sci. 2018 Apr;63(4):966-973. doi: 10.1007/s10620-018-4965-z. Epub 2018 Feb 15.

PMID:
29450749
14.

Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.

Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA.

Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.

PMID:
29361468
15.

Association of Childhood Blood Lead Levels With Criminal Offending.

Beckley AL, Caspi A, Broadbent J, Harrington H, Houts RM, Poulton R, Ramrakha S, Reuben A, Moffitt TE.

JAMA Pediatr. 2018 Feb 1;172(2):166-173. doi: 10.1001/jamapediatrics.2017.4005.

PMID:
29279896
16.

Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab.

Reuben A, Petaccia de Macedo M, McQuade J, Joon A, Ren Z, Calderone T, Conner B, Wani K, Cooper ZA, Tawbi H, Tetzlaff MT, Padera RF, Durand JB, Lazar AJ, Wargo JA, Davies MA.

Oncoimmunology. 2017 Aug 8;6(12):e1361097. doi: 10.1080/2162402X.2017.1361097. eCollection 2017.

17.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

18.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R.

Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.

19.

Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma.

Reuben A, Spencer CN, Prieto PA, Gopalakrishnan V, Reddy SM, Miller JP, Mao X, De Macedo MP, Chen J, Song X, Jiang H, Chen PL, Beird HC, Garber HR, Roh W, Wani K, Chen E, Haymaker C, Forget MA, Little LD, Gumbs C, Thornton RL, Hudgens CW, Chen WS, Austin-Breneman J, Sloane RS, Nezi L, Cogdill AP, Bernatchez C, Roszik J, Hwu P, Woodman SE, Chin L, Tawbi H, Davies MA, Gershenwald JE, Amaria RN, Glitza IC, Diab A, Patel SP, Hu J, Lee JE, Grimm EA, Tetzlaff MT, Lazar AJ, Wistuba II, Clise-Dwyer K, Carter BW, Zhang J, Futreal PA, Sharma P, Allison JP, Cooper ZA, Wargo JA.

NPJ Genom Med. 2017;2. pii: 10. doi: 10.1038/s41525-017-0013-8. Epub 2017 Apr 7.

20.

Toward a Molecular-Genetic Classification of Spitzoid Neoplasms.

Tetzlaff MT, Reuben A, Billings SD, Prieto VG, Curry JL.

Clin Lab Med. 2017 Sep;37(3):431-448. doi: 10.1016/j.cll.2017.05.003. Review.

PMID:
28802494
21.

TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T, Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN Jr, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J.

Cancer Discov. 2017 Oct;7(10):1088-1097. doi: 10.1158/2159-8290.CD-17-0256. Epub 2017 Jul 21.

22.

Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.

Qin Y, Petaccia de Macedo M, Reuben A, Forget MA, Haymaker C, Bernatchez C, Spencer CN, Gopalakrishnan V, Reddy S, Cooper ZA, Fulbright OJ, Ramachandran R, Wahl A, Flores E, Thorsen ST, Tavera RJ, Conrad C, Williams MD, Tetzlaff MT, Wang WL, Gombos DS, Esmaeli B, Amaria RN, Hwu P, Wargo JA, Lazar AJ, Patel SP.

Oncoimmunology. 2017 May 8;6(6):e1321187. doi: 10.1080/2162402X.2017.1321187. eCollection 2017.

23.

Interaction of molecular alterations with immune response in melanoma.

Szczepaniak Sloane RA, Gopalakrishnan V, Reddy SM, Zhang X, Reuben A, Wargo JA.

Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681. Review.

24.

Improved emergency department patient care via rapid assessment and triage.

Reuben AD, Lloyd G.

Br J Hosp Med (Lond). 2017 May 2;78(5):246. doi: 10.12968/hmed.2017.78.5.246. No abstract available.

PMID:
28489435
25.

The hemochromatosis protein HFE 20 years later: An emerging role in antigen presentation and in the immune system.

Reuben A, Chung JW, Lapointe R, Santos MM.

Immun Inflamm Dis. 2017 Sep;5(3):218-232. doi: 10.1002/iid3.158. Epub 2017 Apr 19. Review.

26.

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A.

J Exp Med. 2017 Jun 5;214(6):1691-1710. doi: 10.1084/jem.20160855. Epub 2017 Apr 27.

27.

The Natural History of Severe Acute Liver Injury.

Koch DG, Speiser JL, Durkalski V, Fontana RJ, Davern T, McGuire B, Stravitz RT, Larson AM, Liou I, Fix O, Schilsky ML, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Brown RS, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hanje AJ, Olson J, Subramanian RM, Karvellas C, Hameed B, Sherker AH, Lee WM, Reuben A.

Am J Gastroenterol. 2017 Sep;112(9):1389-1396. doi: 10.1038/ajg.2017.98. Epub 2017 Apr 25.

28.

Association of Childhood Blood Lead Levels With Cognitive Function and Socioeconomic Status at Age 38 Years and With IQ Change and Socioeconomic Mobility Between Childhood and Adulthood.

Reuben A, Caspi A, Belsky DW, Broadbent J, Harrington H, Sugden K, Houts RM, Ramrakha S, Poulton R, Moffitt TE.

JAMA. 2017 Mar 28;317(12):1244-1251. doi: 10.1001/jama.2017.1712.

29.

Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA.

Sci Transl Med. 2017 Mar 1;9(379). pii: eaah3560. doi: 10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12;9(385):.

30.

Enzyme pattern of biliary colic: A counterintuitive picture.

Resnick E, Shteingart S, Melamud B, Bdolah-Abram T, Zalut T, Reuben A, Lurie Y.

World J Hepatol. 2016 Dec 28;8(36):1629-1636. doi: 10.4254/wjh.v8.i36.1629.

31.

Relationship of Abnormal Chromatographic Pattern for Carbohydrate-Deficient Transferrin with Severe Liver Disease.

Stewart SH, Reuben A, Anton RF.

Alcohol Alcohol. 2017 Jan;52(1):24-28. doi: 10.1093/alcalc/agw069. Epub 2016 Oct 7.

32.

Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?

Cogdill AP, Prieto PA, Reuben A, Wargo JA.

Clin Cancer Res. 2017 Jan 15;23(2):327-329. doi: 10.1158/1078-0432.CCR-16-2493. Epub 2016 Nov 11.

33.

Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study.

Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ; Vapreotide Study Group.

J Clin Gastroenterol. 2017 May/Jun;51(5):446-453. doi: 10.1097/MCG.0000000000000733.

34.

Lessons from the REVERT trial.

Appelboam A, Ewings P, Gagg J, Vickery J, Barton A, Reuben A, Mann C, Benger J.

Eur J Emerg Med. 2016 Dec;23(6):459-460. No abstract available.

PMID:
27755149
35.

Lest we forget: comparing retrospective and prospective assessments of adverse childhood experiences in the prediction of adult health.

Reuben A, Moffitt TE, Caspi A, Belsky DW, Harrington H, Schroeder F, Hogan S, Ramrakha S, Poulton R, Danese A.

J Child Psychol Psychiatry. 2016 Oct;57(10):1103-12. doi: 10.1111/jcpp.12621.

36.

An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure.

Roberts DW, Lee WM, Hinson JA, Bai S, Swearingen CJ, Stravitz RT, Reuben A, Letzig L, Simpson PM, Rule J, Fontana RJ, Ganger D, Reddy KR, Liou I, Fix O, James LP.

Clin Gastroenterol Hepatol. 2017 Apr;15(4):555-562.e3. doi: 10.1016/j.cgh.2016.09.007. Epub 2016 Sep 15.

37.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

38.

Monitoring immune responses in the tumor microenvironment.

Wargo JA, Reddy SM, Reuben A, Sharma P.

Curr Opin Immunol. 2016 Aug;41:23-31. doi: 10.1016/j.coi.2016.05.006. Epub 2016 May 27. Review.

39.

Regulation of nucleolin expression by miR-194, miR-206, and HuR.

Bose S, Tholanikunnel TE, Reuben A, Tholanikunnel BG, Spicer EK.

Mol Cell Biochem. 2016 Jun;417(1-2):141-53. doi: 10.1007/s11010-016-2721-2. Epub 2016 May 25.

PMID:
27221739
40.

Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy.

Reddy SM, Reuben A, Wargo JA.

Curr Oncol Rep. 2016 Jul;18(7):42. doi: 10.1007/s11912-016-0531-z. Review.

41.

Density, Distribution, and Composition of Immune Infiltrates Correlate with Survival in Merkel Cell Carcinoma.

Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B, Rodriguez-Canales J, Reuben A, Chen PL, Ko JS, Billings SD, Bassett RL, Wistuba II, Cooper ZA, Prieto VG, Wargo JA, Tetzlaff MT.

Clin Cancer Res. 2016 Nov 15;22(22):5553-5563. doi: 10.1158/1078-0432.CCR-16-0392. Epub 2016 May 10.

42.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

43.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.

JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509.

44.

Targeted Therapies Combined With Immune Checkpoint Therapy.

Prieto PA, Reuben A, Cooper ZA, Wargo JA.

Cancer J. 2016 Mar-Apr;22(2):138-46. doi: 10.1097/PPO.0000000000000182. Review.

PMID:
27111910
45.

Development of a Model to Predict Transplant-free Survival of Patients With Acute Liver Failure.

Koch DG, Tillman H, Durkalski V, Lee WM, Reuben A.

Clin Gastroenterol Hepatol. 2016 Aug;14(8):1199-1206.e2. doi: 10.1016/j.cgh.2016.03.046. Epub 2016 Apr 13.

46.

Outcomes in Adults With Acute Liver Failure Between 1998 and 2013: An Observational Cohort Study.

Reuben A, Tillman H, Fontana RJ, Davern T, McGuire B, Stravitz RT, Durkalski V, Larson AM, Liou I, Fix O, Schilsky M, McCashland T, Hay JE, Murray N, Shaikh OS, Ganger D, Zaman A, Han SB, Chung RT, Smith A, Brown R, Crippin J, Harrison ME, Koch D, Munoz S, Reddy KR, Rossaro L, Satyanarayana R, Hassanein T, Hanje AJ, Olson J, Subramanian R, Karvellas C, Hameed B, Sherker AH, Robuck P, Lee WM.

Ann Intern Med. 2016 Jun 7;164(11):724-32. doi: 10.7326/M15-2211. Epub 2016 Apr 5.

47.

Working with Human Tissues for Translational Cancer Research.

Reuben A, Gopalakrishnan V, Wagner HE, Spencer CN, Austin-Breneman J, Jiang H, Cooper ZA, Wargo JA.

J Vis Exp. 2015 Nov 26;(105). doi: 10.3791/53189.

48.

Raising the bar: optimizing combinations of targeted therapy and immunotherapy.

Reuben A, Austin-Breneman J, Wargo JA, Cooper ZA.

Ann Transl Med. 2015 Oct;3(18):272. doi: 10.3978/j.issn.2305-5839.2015.10.28. No abstract available.

49.

Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver Failure.

Stravitz RT, Ellerbe C, Durkalski V, Reuben A, Lisman T, Lee WM; Acute Liver Failure Study Group.

Clin Gastroenterol Hepatol. 2016 Apr;14(4):613-620.e4. doi: 10.1016/j.cgh.2015.09.029. Epub 2015 Dec 10.

50.

Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy.

Wargo JA, Reuben A, Cooper ZA, Oh KS, Sullivan RJ.

Semin Oncol. 2015 Aug;42(4):601-16. doi: 10.1053/j.seminoncol.2015.05.007. Epub 2015 Jun 3. Review.

Supplemental Content

Loading ...
Support Center